Detalhe da pesquisa
1.
Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer.
N Engl J Med
; 389(16): 1453-1465, 2023 Oct 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-37851874
2.
Apalutamide efficacy, safety and wellbeing in older patients with advanced prostate cancer from Phase 3 randomised clinical studies TITAN and SPARTAN.
Br J Cancer
; 130(1): 73-81, 2024 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37951974
3.
Extended Safety and Tolerability of Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer and Adverse Event Time Course in ARAMIS.
Oncologist
; 2024 Feb 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-38394384
4.
Impact of darolutamide on local symptoms: pre-planned and post hoc analyses of the ARAMIS trial.
BJU Int
; 131(4): 452-460, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36087070
5.
A US real-world study of treatment patterns and outcomes in localized or locally advanced prostate cancer patients.
World J Urol
; 41(12): 3535-3542, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37966506
6.
Optimizing the management of castration-resistant prostate cancer patients: A practical guide for clinicians.
Prostate
; 80(14): 1159-1176, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32779781
7.
Real-world outcomes of sipuleucel-T treatment in PROCEED, a prospective registry of men with metastatic castration-resistant prostate cancer.
Cancer
; 125(23): 4172-4180, 2019 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31483485
8.
Reply to Potential underestimation of cerebrovascular events in the PROVENGE Registry for the Observation, Collection, and Evaluation of Experience Data.
Cancer
; 126(12): 2935-2937, 2020 06 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32154908
9.
TARGET: A Randomized, Noninferiority Trial of a Pretest, Patient-Driven Genetic Education Webtool Versus Genetic Counseling for Prostate Cancer Germline Testing.
JCO Precis Oncol
; 8: e2300552, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38452310
10.
Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials.
Clin Cancer Res
; 29(13): 2426-2434, 2023 07 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37058234
11.
Enzalutamide and Quality of Life in Biochemically Recurrent Prostate Cancer.
NEJM Evid
; 2(12): EVIDoa2300251, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-38320501
12.
Efficacy of National Comprehensive Cancer Network Guidelines in Identifying Pathogenic Germline Variants Among Unselected Patients with Prostate Cancer: The PROCLAIM Trial.
Eur Urol Oncol
; 6(5): 477-483, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-37574391
13.
Development and evaluation of the MiCheck® Prostate test for clinically significant prostate cancer.
Urol Oncol
; 41(11): 454.e9-454.e16, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37734979
14.
Concomitant use of oral anticoagulants in patients with advanced prostate cancer receiving apalutamide: A post-hoc analysis of TITAN and SPARTAN studies.
Am J Cancer Res
; 12(1): 445-450, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35141028
15.
A Phase Ib/II Study of Sabizabulin, a Novel Oral Cytoskeleton Disruptor, in Men with Metastatic Castration-resistant Prostate Cancer with Progression on an Androgen Receptor-targeting Agent.
Clin Cancer Res
; 28(13): 2789-2795, 2022 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35416959
16.
Technology-enhanced AcceleRation of Germline Evaluation for Therapy (TARGET): A randomized controlled trial of a pretest patient-driven webtool vs. genetic counseling for prostate cancer germline testing.
Contemp Clin Trials
; 119: 106821, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35710085
17.
Bone health effects of androgen-deprivation therapy and androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer.
Prostate Cancer Prostatic Dis
; 24(2): 290-300, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33028943
18.
The Oral Gonadotropin-releasing Hormone Receptor Antagonist Relugolix as Neoadjuvant/Adjuvant Androgen Deprivation Therapy to External Beam Radiotherapy in Patients with Localised Intermediate-risk Prostate Cancer: A Randomised, Open-label, Parallel-group Phase 2 Trial.
Eur Urol
; 78(2): 184-192, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32273183
19.
Development and evaluation of the MiCheck test for aggressive prostate cancer.
Urol Oncol
; 38(8): 683.e11-683.e18, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32305266
20.
A comparison of prostate health index, total PSA, %free PSA, and proPSA in a contemporary US population-The MiCheck-01 prospective trial.
Urol Oncol
; 38(8): 683.e1-683.e10, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32360170